Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease
Prospective Open-Label Trial of Etanercept as Adjunctive Therapy for Kawasaki Disease
复制标题
DOI：
10.1016/j.jpeds.2010.06.014
复制
发表时间：
2010-12-01
影响因子：
5.1
通讯作者：
Portman, Michael A.
中科院分区：
文献类型：
--
作者：
Choueiter, Nadine F.;Olson, Aaron K.;Portman, Michael A.
目的 确定依那西普（Amgen，千橡市，加利福尼亚州）（一种肿瘤坏死因子 -a 受体阻滞剂）在急性川崎病 (KD) 儿童中的安全性和药代动力学。急性川崎病的标准治疗包括静脉注射免疫球蛋白 (IVIG) 和大剂量阿司匹林，但大量患者难以治疗，需要额外治疗。川崎病儿童的肿瘤坏死因子-a 水平升高，表明依那西普在治疗中发挥作用。 研究设计 我们对符合临床标准且伴有发热的川崎病患者（年龄范围，6 个月至 5 岁；n = 17）进行了一项前瞻性开放标签试验。
Objective To determine the safety and pharmacokinetics of etanercept (Amgen, Thousand Oaks, California) a tumor necrosis factor-a receptor blocker, in children with acute Kawasaki disease (KD). Standard therapy of acute KD includes intravenous immunoglobulin (IVIG) and high-dose aspirin, but a substantial number of patients are refractory and require additional treatment. Tumor necrosis factor-a levels are elevated in children with KD, suggesting a role for etanercept in treatment.Study design We performed a prospective open-label trial of etanercept in patients with KD (age range, 6 months-5 years; n = 17) meeting clinical criteria and with fever